Profile of Panobinostat and Its Potential for Treatment in Solid Tumors: an Update

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2013 Nov 23

PMID 24265556

Citations 34

Authors

Madhurima Anne

Daniel Sammartino

Myra F Barginear

Daniel Budman

Affiliations

Soon will be listed here.

Abstract

The histone deacetylase (HDAC) inhibitors have emerged as novel therapies for cancer. Panobinostat (LBH 589, Novartis Pharmaceuticals) is a pan-deacetylase inhibitor that is being evaluated in both intravenous and oral formulations across multiple tumor types. Comparable to the other HDACs, panobinostat leads to hyperacetylation of histones and other intracellular proteins, allowing for the expression of otherwise repressed genes, leading to inhibition of cellular proliferation and induction of apoptosis in malignant cells. Panobinostat, analogous to other HDAC inhibitors, also induces apoptosis by directly activating cellular death receptor pathways. Preclinical data suggests that panobinostat has inhibitory activity at nanomolar concentrations and appears to be the most potent clinically available HDAC inhibitor. Here we review the current status of panobinostat and discuss its role in the treatment of solid tumors.

Citing Articles

Upregulated spinal histone deacetylases induce nociceptive sensitization by inhibiting the GABA system in chronic constriction injury-induced neuropathy in rats.

Wen Z, Chen N, Cheng H, Kuo H, Chen P, Feng C Pain Rep. 2024; 9(6):e1209.

PMID: 39512583 PMC: 11543203. DOI: 10.1097/PR9.0000000000001209.

Dysregulated Forkhead Box (FOX) Genes Association with Survival Prognosis, Anti-tumor Immunity, and Key Targeting Drugs in Colon Adenocarcinoma.

Xie Q, Wang J, Peng X Arch Iran Med. 2024; 26(9):510-528.

PMID: 38310407 PMC: 10862056. DOI: 10.34172/aim.2023.77.

MRI-guided focused ultrasound blood-brain barrier opening increases drug delivery and efficacy in a diffuse midline glioma mouse model.

Martinez P, Nault G, Steiner J, Wempe M, Pierce A, Brunt B Neurooncol Adv. 2023; 5(1):vdad111.

PMID: 37795179 PMC: 10547466. DOI: 10.1093/noajnl/vdad111.

Investigations on the cytotoxicity and antimicrobial activities of terezine E and 14-hydroxyterezine D.

Mojally M, Abdou R, Bokhari W, Sab S, Dawoud M, Albohy A Braz J Med Biol Res. 2023; 56:e12404.

PMID: 37042868 PMC: 10085759. DOI: 10.1590/1414-431X2023e12404.

Recent Advancement in Anticancer Compounds from Marine Organisms: Approval, Use and Bioinformatic Approaches to Predict New Targets.

Santaniello G, Nebbioso A, Altucci L, Conte M Mar Drugs. 2023; 21(1).

PMID: 36662197 PMC: 9862894. DOI: 10.3390/md21010024.

References

Venkannagari S, Fiskus W, Peth K, Atadja P, Hidalgo M, Maitra A . Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer. Oncotarget. 2012; 3(11):1416-27. PMC: 3717802. DOI: 10.18632/oncotarget.724. View

Zopf S, Ocker M, Neureiter D, Alinger B, Gahr S, Neurath M . Inhibition of DNA methyltransferase activity and expression by treatment with the pan-deacetylase inhibitor panobinostat in hepatocellular carcinoma cell lines. BMC Cancer. 2012; 12:386. PMC: 3487800. DOI: 10.1186/1471-2407-12-386. View

Rathkopf D, Wong B, Ross R, Anand A, Tanaka E, Woo M . A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2010; 66(1):181-9. DOI: 10.1007/s00280-010-1289-x. View

Gahr S, Wissniowski T, Zopf S, Strobel D, Pustowka A, Ocker M . Combination of the deacetylase inhibitor panobinostat and the multi-kinase inhibitor sorafenib for the treatment of metastatic hepatocellular carcinoma - review of the underlying molecular mechanisms and first case report. J Cancer. 2012; 3:158-65. PMC: 3328781. DOI: 10.7150/jca.4211. View

Clive S, Woo M, Nydam T, Kelly L, Squier M, Kagan M . Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients. Cancer Chemother Pharmacol. 2012; 70(4):513-22. DOI: 10.1007/s00280-012-1940-9. View

Budman D, Tai J, Calabro A, John V . The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines. Invest New Drugs. 2010; 29(6):1224-9. DOI: 10.1007/s10637-010-9467-6. View

Rao R, Balusu R, Fiskus W, Mudunuru U, Venkannagari S, Chauhan L . Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells. Mol Cancer Ther. 2012; 11(4):973-83. DOI: 10.1158/1535-7163.MCT-11-0979. View

Minucci S, Pelicci P . Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006; 6(1):38-51. DOI: 10.1038/nrc1779. View

Gridelli C, Rossi A, Maione P . The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer. Crit Rev Oncol Hematol. 2008; 68(1):29-36. DOI: 10.1016/j.critrevonc.2008.03.002. View

10.

Marks P, Xu W . Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem. 2009; 107(4):600-8. PMC: 2766855. DOI: 10.1002/jcb.22185. View

11.

Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F . Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem. 2005; 280(29):26729-34. DOI: 10.1074/jbc.C500186200. View

12.

Dawson M, Kouzarides T . Cancer epigenetics: from mechanism to therapy. Cell. 2012; 150(1):12-27. DOI: 10.1016/j.cell.2012.06.013. View

13.

Fukutomi A, Hatake K, Matsui K, Sakajiri S, Hirashima T, Tanii H . A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors. Invest New Drugs. 2011; 30(3):1096-106. DOI: 10.1007/s10637-011-9666-9. View

14.

Dickinson M, Johnstone R, Prince H . Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. Invest New Drugs. 2010; 28 Suppl 1:S3-20. PMC: 3003794. DOI: 10.1007/s10637-010-9596-y. View

15.

Tan W, Allred J, Moreno-Aspitia A, Northfelt D, Ingle J, Goetz M . Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients. Clin Breast Cancer. 2016; 16(2):82-6. PMC: 5567753. DOI: 10.1016/j.clbc.2015.11.003. View

16.

DeAngelo D, Spencer A, Bhalla K, Prince H, Fischer T, Kindler T . Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia. 2013; 27(8):1628-36. DOI: 10.1038/leu.2013.38. View

17.

Wang H, Cao Q, Dudek A . Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy. Anticancer Res. 2012; 32(3):1027-31. View

18.

Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y, Villanueva A . Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J Hepatol. 2012; 56(6):1343-50. PMC: 3355195. DOI: 10.1016/j.jhep.2012.01.009. View

19.

Hamberg P, Woo M, Chen L, Verweij J, Porro M, Zhao L . Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor. Cancer Chemother Pharmacol. 2011; 68(3):805-13. PMC: 3162150. DOI: 10.1007/s00280-011-1693-x. View

20.

Crisanti M, Wallace A, Kapoor V, Vandermeers F, Dowling M, Pereira L . The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer. Mol Cancer Ther. 2009; 8(8):2221-31. PMC: 3605895. DOI: 10.1158/1535-7163.MCT-09-0138. View